The Small Fiber Neuropathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Small Fiber Neuropathy pipeline products will significantly revolutionize the Small Fiber Neuropathy market dynamics.
DelveInsight’s “Small Fiber Neuropathy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Small Fiber Neuropathy, historical and forecasted epidemiology as well as the Small Fiber Neuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Small Fiber Neuropathy market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Small Fiber Neuropathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Small Fiber Neuropathy Market Insights
Some of the key facts of the Small Fiber Neuropathy Market Report:
The Small Fiber Neuropathy market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
In May 2025, Novaremed AG, a privately owned clinical-stage biopharmaceutical company, has announced the completion of patient enrollment in the Phase 2b EN21-01 trial (ClinicalTrials.gov ID: NCT05480228), sponsored by the National Institutes of Health (NIH). The study is assessing NRD.E1, a non-opioid investigational drug, for treating chronic pain linked to diabetic peripheral neuropathy. The trial is supported by the NIH’s Helping to End Addiction Long-term (HEAL) Initiative. Topline results from the Phase 2b trial are anticipated in the fourth quarter of 2025.
In March 2025, Lexicon Pharmaceuticals’ non-opioid therapy showed superior results compared to placebo at a 10mg dose in patients suffering from severe diabetic peripheral neuropathic pain (DPNP). In the Phase II Progress study (NCT06203002), which included 600 participants with DPNP, the treatment led to significant reductions in the average daily pain score (ADPS) from baseline through the eighth week.
In October 2024, Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a clinical-stage company specializing in targeted immunotherapeutic drugs, has signed a licensing agreement with Alkem Laboratories Limited. This agreement grants Alkem the rights for research, development, manufacturing, marketing, and commercialization of SON-080 for diabetic peripheral neuropathy (DPN) in India. Additionally, Alkem will oversee the manufacturing, marketing, and commercialization of SON-080 for chemotherapy-induced neuropathy (CIPN) and autonomic neuropathy within India. SON-080 operates through the same mechanism of action across all three neuropathies
In 2023, there were approximately 34 million prevalent cases of diabetic peripheral neuropathy in the 7MM, with the United States having the highest number of cases.
In 2023, the US represented nearly half of all treated cases, and this number is projected to grow by 2034.
The market offers several approved drugs to alleviate pain caused by Small Fiber Neuropathy, including antiseizure medications, antidepressants, opioids, and non-opioid pain relief options. Common antiseizure drugs used for symptomatic pain relief include LYRICA (Pfizer), NUCYNTA (Assertio Therapeutics, formerly Depomed), CYMBALTA (Eli Lilly), EFFEXOR (Pfizer), and QUTENZA (Averitas). However, their use is often linked to undesirable side effects.
In 2023, peripheral diabetic neuropathy accounted for the largest number of type-specific cases of diabetic neuropathy in the 7MM.
Key Small Fiber Neuropathy Companies: Vertex Pharmaceuticals, Grünenthal, Averitas Pharma, Daiichi Sankyo, Helixmith, Lexicon Pharmaceuticals, Glenmark Pharmaceuticals, Regenacy Pharmaceuticals, Pure Green, and others
Key Small Fiber Neuropathy Therapies: VX-150, QUTENZA (capsaicin), TARLIGE (mirogabalin besylate), Engensis (VM202), Suzetrigine (VX-548), VM202, LX9211, GRC 17536, Ricolinostat, CBD, and others
The Small Fiber Neuropathy epidemiology based on gender analyzed that the prevalence of Small Fiber Neuropathy increases significantly with age
Small Fiber Neuropathy Overview
Small Fiber Neuropathy is a neurological disorder that affects the small nerve fibers responsible for pain, temperature sensation, and autonomic functions (like heart rate and sweating). Unlike large fiber neuropathies, Small Fiber Neuropathy often causes burning pain, tingling, numbness, or electric-shock-like sensations, typically in the feet and hands. It can also lead to symptoms like dry eyes, gastrointestinal issues, or abnormal sweating. Small Fiber Neuropathy may result from conditions like diabetes, autoimmune diseases, infections, or can be idiopathic (unknown cause). Diagnosis often requires specialized tests such as skin biopsy or quantitative sensory testing, as standard nerve conduction studies may appear normal.
Get a Free sample for the Small Fiber Neuropathy Market Report:
https://www.delveinsight.com/report-store/small-fiber-neuropathy-market
Small Fiber Neuropathy Market
The dynamics of the Small Fiber Neuropathy market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecast period 2019-2032.
Small Fiber Neuropathy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Small Fiber Neuropathy Epidemiology Segmentation:
The Small Fiber Neuropathy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Prevalent Cases of Small Fiber Neuropathy in the 7MM
Prevalent Cases of Painful Small Fiber Neuropathy in the 7MM
Treated Cases of Small Fiber Neuropathy in the 7MM
Download the report to understand which factors are driving Small Fiber Neuropathy epidemiology trends @ Small Fiber Neuropathy Epidemiological Insights
Small Fiber Neuropathy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Small Fiber Neuropathy market or expected to get launched during the study period. The analysis covers Small Fiber Neuropathy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Small Fiber Neuropathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Small Fiber Neuropathy Therapies and Key Companies
QUTENZA (capsaicin): Grünenthal/Averitas Pharma
VX-150: Vertex Pharmaceuticals
TARLIGE (mirogabalin besylate): Daiichi Sankyo
Engensis (VM202): Helixmith
Suzetrigine (VX-548): Vertex Pharmaceuticals
VM202: Helixmith
LX9211: Lexicon Pharmaceuticals
GRC 17536: Glenmark Pharmaceuticals
Ricolinostat: Regenacy Pharmaceuticals
CBD: Pure Green
To know more about Small Fiber Neuropathy treatment, visit @ Small Fiber Neuropathy Medications
Small Fiber Neuropathy Market Drivers
Small Fiber Neuropathy is a complex disorder, efforts have been made by researchers and scientific professionals to improve the understanding of the pathogenesis and diagnosis of this condition.
Treatment of Small Fiber Neuropathy has improved significantly in recent years with the availability of several safe and effective therapies. Several consensus guidelines have been created to further assist in the management of Small Fiber Neuropathy patients.
Small Fiber Neuropathy Market Unmet Needs
Challenges in diagnosis
Development of novel therapies
Limitations in gene therapy
Poor disease understanding
Clinical biomarkers
Scope of the Small Fiber Neuropathy Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Small Fiber Neuropathy Therapeutic Assessment: Small Fiber Neuropathy current marketed and Small Fiber Neuropathy emerging therapies
Small Fiber Neuropathy Market Dynamics: Small Fiber Neuropathy market drivers and Small Fiber Neuropathy market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Small Fiber Neuropathy Unmet Needs, KOL’s views, Analyst’s views, Small Fiber Neuropathy Market Access and Reimbursement
Discover more about therapies set to grab major Small Fiber Neuropathy market share @ Small Fiber Neuropathy Treatment Landscape
Table of Contents
1. Small Fiber Neuropathy Market Report Introduction
2. Executive Summary for Small Fiber Neuropathy
3. SWOT analysis of Small Fiber Neuropathy
4. Small Fiber Neuropathy Patient Share (%) Overview at a Glance
5. Small Fiber Neuropathy Market Overview at a Glance
6. Small Fiber Neuropathy Disease Background and Overview
7. Small Fiber Neuropathy Epidemiology and Patient Population
8. Country-Specific Patient Population of Small Fiber Neuropathy
9. Small Fiber Neuropathy Current Treatment and Medical Practices
10. Small Fiber Neuropathy Unmet Needs
11. Small Fiber Neuropathy Emerging Therapies
12. Small Fiber Neuropathy Market Outlook
13. Country-Wise Small Fiber Neuropathy Market Analysis (2019–2032)
14. Small Fiber Neuropathy Market Access and Reimbursement of Therapies
15. Small Fiber Neuropathy Market Drivers
16. Small Fiber Neuropathy Market Barriers
17. Small Fiber Neuropathy Appendix
18. Small Fiber Neuropathy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
